Last reviewed · How we verify
AV024
AV024 is a monoclonal antibody that targets and inhibits IL-6 signaling to reduce inflammatory responses.
AV024 is a monoclonal antibody that targets and inhibits IL-6 signaling to reduce inflammatory responses. Used for Systemic sclerosis (scleroderma), Other fibrotic or inflammatory conditions.
At a glance
| Generic name | AV024 |
|---|---|
| Sponsor | MedImmune LLC |
| Drug class | IL-6 inhibitor monoclonal antibody |
| Target | IL-6 or IL-6 receptor |
| Modality | Biologic |
| Therapeutic area | Immunology |
| Phase | Phase 3 |
Mechanism of action
AV024 binds to IL-6 or IL-6 receptor to block interleukin-6 mediated inflammation, which plays a key role in various inflammatory and autoimmune conditions. By neutralizing IL-6 signaling, the drug aims to reduce systemic inflammation and disease progression in conditions where IL-6 is pathologically elevated.
Approved indications
- Systemic sclerosis (scleroderma)
- Other fibrotic or inflammatory conditions
Common side effects
- Infection
- Infusion reactions
- Laboratory abnormalities
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- AV024 CI brief — competitive landscape report
- AV024 updates RSS · CI watch RSS
- MedImmune LLC portfolio CI